MTOR and plasma cell myeloma: Lamanuzzi et al. reported that mTORC2 regulates tumor angiogenesis in multiple myeloma (MM), and suggested that the combined mTOR inhibitor PP242 with lenalidomide and bortezomib exhibited synergistic activities in inhibiting angiogenesis in vivo in the Chick Chorioallantoic Membrane (CAM) and Matrigel®® plug assays [63].